8.250USD+13.01%Mkt Cap: 4.38M USDP/E: 0.08Last update: 2026-05-26
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (I…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap4.38M USD
Enterprise Value-7.67M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-12.52M USD
Revenue/Share—
Last Price8.250 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees11
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.08
P/E (Forward)-0.33
PEG—
EV/EBITDA1.88
EV/Revenue—
P/S—
P/B0.58
EPS (TTM)106.79
EPS (Forward)-19.32
52W Range
4.3201% of range415.80
52W High415.80 USD
52W Low4.320 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-212.58%
ROA-113.22%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.83M USD
CapEx (TTM)577.00K USD
FCF Margin—
FCF Yield41.62%
Net Debt-10.71M USD
Net Debt/EBITDA2.62
Balance Sheet
Debt/Equity—
Current Ratio2.13
Quick Ratio2.07
Book Value/Sh11.07 USD
Cash/Share20.13 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateMar 9, 2026
Analyst Consensus
Rating—
Target (Mean)30.00 USD
Target Range30.00 USD – 30.00 USD
# Analysts1
Ownership
Shares Out.531.97K
Float528.44K
Insiders0.58%
Institutions12.01%
Short Interest
Short Ratio0.8d
Short % Float4.37%
Short % Out.4.37%
Shares Short23.25K
Short (prev mo.)28.91K
Technical
SMA 506.135 (+34.5%)
SMA 20024.91 (-66.9%)
Beta0.38
S&P 52W Chg28.31%
Avg Vol (30d)11.58K
Avg Vol (10d)12.25K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—